Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias

J Antimicrob Chemother. 2014 Jan;69(1):284-5. doi: 10.1093/jac/dkt306. Epub 2013 Aug 9.

Authors

Giovanni Guaraldi¹, Giovanni Dolci, Antonio Bellasi

Affiliation

¹ Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.

PMID: 23934771
DOI: 10.1093/jac/dkt306

No abstract available

Keywords: chronic kidney disease; metabolic syndrome; protease inhibitors.

Publication types

Letter

MeSH terms

Anti-HIV Agents / administration & dosage
Anti-HIV Agents / adverse effects*
Atazanavir Sulfate
Diagnosis, Differential
Humans
Oligopeptides / administration & dosage
Oligopeptides / adverse effects*
Pyridines / administration & dosage
Pyridines / adverse effects*
Renal Insufficiency, Chronic / diagnosis
Renal Insufficiency, Chronic / pathology
Urolithiasis / chemically induced*
Urolithiasis / diagnosis*

Substances

Anti-HIV Agents
Oligopeptides
Pyridines
Atazanavir Sulfate